Form 8-K · Current Report · Filed 2025-06-10
Ionis Pharmaceuticals Annual Meeting Voting Results Announced
Ionis Pharmaceuticals, Inc. held its virtual Annual Meeting of Stockholders on June 5, 2025, where stockholders approved several key proposals. These included the election of directors for the 2028 Annual Meeting, an advisory vote on executive compensation, an amendment to increase the number of shares authorized under the 2011 Equity Incentive Plan, and the ratification of Ernst & Young LLP as independent auditors for the 2025 fiscal year. All proposals were approved by a majority of the votes cast, as detailed in the Company's definitive proxy statement dated April 25, 2025.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001140361-25-022001
- CIK
- 0000874015
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Submission of Matters to a Vote of Security Holders
Financial Statements and Exhibits
Market reaction
Close before filing
$36.76
Next session
-1.6%
Since filing
+40.8%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.